Adamas Pharmaceuticals, Inc. (ADMS) Given Overweight Rating at Piper Jaffray Companies

Piper Jaffray Companies reissued their overweight rating on shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a research report report published on Friday, September 1st. They currently have a $30.00 price target on the specialty pharmaceutical company’s stock. The analysts noted that the move was a valuation call.

Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, May 12th. Noble Financial reiterated a buy rating on shares of Adamas Pharmaceuticals in a research note on Friday, May 12th. BidaskClub cut shares of Adamas Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, July 19th. Mizuho restated a buy rating and set a $26.00 target price on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. Finally, Cowen and Company restated an outperform rating and set a $45.00 target price on shares of Adamas Pharmaceuticals in a research note on Sunday, May 28th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $33.00.

Shares of Adamas Pharmaceuticals (NASDAQ ADMS) opened at 21.53 on Friday. The company has a 50 day moving average of $18.00 and a 200-day moving average of $17.19. The firm’s market cap is $484.73 million. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $22.58.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 52.91%. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. During the same quarter in the prior year, the company posted ($0.78) EPS. Adamas Pharmaceuticals’s revenue was down 90.9% on a year-over-year basis. On average, analysts expect that Adamas Pharmaceuticals will post ($3.79) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Given Overweight Rating at Piper Jaffray Companies” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://ledgergazette.com/2017/09/17/adamas-pharmaceuticals-inc-adms-receives-overweight-rating-from-piper-jaffray-companies.html.

In related news, major shareholder Great Point Partners Llc sold 380,000 shares of the firm’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $17.08, for a total value of $6,490,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. American International Group Inc. lifted its position in Adamas Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 682 shares during the last quarter. Alps Advisors Inc. lifted its position in Adamas Pharmaceuticals by 6.7% in the second quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock worth $353,000 after buying an additional 1,272 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Adamas Pharmaceuticals by 2.4% in the first quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock worth $1,152,000 after buying an additional 1,563 shares during the last quarter. Wells Fargo & Company MN lifted its position in Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 3,358 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Adamas Pharmaceuticals by 4.9% in the first quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock worth $2,201,000 after buying an additional 5,920 shares during the last quarter. Institutional investors own 69.24% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply